Furmonertinib: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Furmonertinib

• A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
  NCT07229599 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
  NCT07622186 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
  NCT06643000 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
  NCT06674343 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  NCT07304739 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
  NCT05334277 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
  NCT05379803 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
  NCT06394674 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
  NCT05503667 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
  NCT06192849 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Furmonertinib?

10 recruiting trials across 9 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.